Soleno Therapeutics Inc (SLNO)

Dec 17, 2024, 4:05 PM EST - 4 weeks ago

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

Nov 27, 2024, 8:00 AM EST - 7 weeks ago

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:30 AM EST - 7 weeks ago

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Nov 14, 2024, 4:05 PM EST - 2 months ago

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Oct 10, 2024, 2:53 PM EDT - 3 months ago

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Oct 8, 2024, 6:51 PM EDT - 3 months ago

SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval

Oct 3, 2024, 12:03 PM EDT - 3 months ago

Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc

JHG

Sep 16, 2024, 4:05 PM EDT - 4 months ago

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 27, 2024, 1:00 PM EDT - 5 months ago

Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients

Aug 27, 2024, 8:00 AM EDT - 5 months ago

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Aug 19, 2024, 4:17 PM EDT - 5 months ago

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 28, 2024, 8:00 AM EDT - 7 months ago

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

May 22, 2024, 4:05 PM EDT - 8 months ago

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

May 22, 2024, 8:00 AM EDT - 8 months ago

Soleno Therapeutics to Participate in Upcoming Investor Conferences

May 15, 2024, 8:00 AM EDT - 8 months ago

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

May 9, 2024, 4:05 PM EDT - 9 months ago

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 10:32 PM EDT - 9 months ago

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock

May 2, 2024, 4:01 PM EDT - 9 months ago

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Apr 30, 2024, 8:00 AM EDT - 9 months ago

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome

Apr 29, 2024, 4:02 PM EDT - 9 months ago

Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch

Apr 29, 2024, 8:00 AM EDT - 9 months ago

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Mar 6, 2024, 4:05 PM EST - 11 months ago

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 22, 2024, 8:00 AM EST - 11 months ago

Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 1, 2024, 8:00 AM EST - 1 year ago

Soleno Therapeutics to Present at Upcoming February Investor Conferences

Jan 24, 2024, 8:00 AM EST - 1 year ago

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Jan 22, 2024, 10:42 PM EST - 1 year ago

Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families

ACAD

Dec 27, 2023, 2:46 PM EST - 1 year ago

The best-performing stock of the year rose nearly 10-fold, while the second-best averted disaster to surge 1,000% in a wild 2023

CVNA

Nov 26, 2023, 10:47 AM EST - 1 year ago

Soleno Therapeutics: Impressive Data, But Never Forget Amarin

Nov 7, 2023, 8:00 AM EST - 1 year ago

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 8:00 AM EST - 1 year ago

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome

Oct 4, 2023, 6:16 PM EDT - 1 year ago

Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

Oct 4, 2023, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

Oct 2, 2023, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 28, 2023, 8:30 AM EDT - 1 year ago

Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

Sep 27, 2023, 4:01 PM EDT - 1 year ago

Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

Sep 27, 2023, 1:28 PM EDT - 1 year ago

Soleno Stock Dives After Its Meteoric Rise

Sep 26, 2023, 7:30 AM EDT - 1 year ago

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Sep 25, 2023, 8:00 AM EDT - 1 year ago

Soleno Therapeutics to Present at the Cantor Global Healthcare Conference

Aug 16, 2023, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

May 9, 2023, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 3, 2023, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Mar 28, 2023, 8:00 AM EDT - 1 year ago

Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days

Mar 21, 2023, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

Mar 7, 2023, 8:00 AM EST - 2 years ago

Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Jan 26, 2023, 8:00 AM EST - 2 years ago

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Dec 19, 2022, 8:00 AM EST - 2 years ago

Soleno Therapeutics Announces Financing Commitment for up to $60 Million

Nov 9, 2022, 4:05 PM EST - 2 years ago

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Oct 3, 2022, 8:00 AM EDT - 2 years ago

Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome